Back to search

University of British Columbia

An analysis of heart failure reduced ejection fraction pharmacotherapy sequencing strategies

Abstract

dc:description

Introduction: Heart failure with reduced ejection fraction (HFrEF) is a debilitating condition that can be managed with pharmacotherapy, consisting of an angiotensin receptor- neprilysin inhibitor (ARNI), a beta-blocker (BB), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter-2 inhibitor (SGLT2I). However, the optimal process of initiating and titrating these medications, known as sequencing strategy, is widely debated. Methods and Results: A scoping review was conducted to identify ambulatory sequencing strategies for treatment-naïve, de novo HFrEF patients, revealing a trend in the selection of attributes from the identified strategies, with a focus on expediting the initiation of quadruple therapy. Two attributes were found to heavily influence this trend: the number of medications initiated during the first visit and whether to prioritize initiation or titration. Based on these attributes, we developed a framework to classify sequencing strategies into 3 strategy types, and proposed 2 profiles to represent each type. A benefit-harm and cost-utility analysis was performed using an individual-based state-transition microsimulation model, where each profile was modeled in 2 versions with medication adjustment made fortnightly (a) or weekly (b). Probabilistic analysis of 10,000 trials and 1,000 samples with a willingness-to-pay threshold of $50,000/QALY were conducted, along with one-way sensitivity analysis, and 2 scenario analyses. The analysis demonstrated that the incremental cost-effectiveness among the different strategies is minimal, favoring more intensive strategies after considering benefits, harms and costs. In the base scenario, “simultaneous” sequencing strategy with fortnightly adjustment (Profile 6a) was most likely to be cost-effective. However, in the scenario where sub-target doses were assumed to be ineffective, strategies involved weekly adjustment were more likely to be optimal compared to fortnightly adjustment. In the scenario where medication adjustments were stopped after 3 months, “traditional” sequencing strategy with fortnightly adjustment (Profile 1a) failed to achieve quadruple therapy, resulting in substantially fewer benefits. Conclusions: There was a noticeable trend towards prioritizing the speed of sequencing HFrEF quadruple therapy in the literature. However, this analysis revealed that the incremental cost-effectiveness among the different strategies was marginal. The key factor determining optimal outcomes was the successful establishment of patients on quadruple therapy within a reasonable timeframe.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Pharmaceutical Sciences
Grantor dc:publisher
University of British Columbia
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Van, Minh Tri
Contributors dc:contributor
  • Turgeon, Ricky
  • Loewen, Peter

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/85637

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Van, Minh Tri. An analysis of heart failure reduced ejection fraction pharmacotherapy sequencing strategies. master's thesis, University of British Columbia, 2023. http://hdl.handle.net/2429/85637